All Updates

All Updates

icon
Filter
Partnerships
AbSci receives strategic investment from Merck Global Health Innovation Fund
AI Drug Discovery
Feb 22, 2021
This week:
Partnerships
Apple discloses use of AWS GenAI chips at re:Invent 2024 conference
Generative AI Infrastructure
Today
Product updates
AWS launches Automated Reasoning checks to combat AI hallucinations
Generative AI Infrastructure
Today
Product updates
Roonyx releases enhanced BNPL platform to facilitate secure transactions
Buy Now, Pay Later
Yesterday
Product updates
AWS announces next generation of SageMaker platform at re:Invent 2024
Generative AI Infrastructure
Yesterday
Product updates
Equal1 launches quantum controller chip for cryogenic computing
Quantum Computing
Yesterday
Partnerships
Exotec partners with BlueStar to deploy Skypod warehouse automation system
Logistics Tech
Yesterday
Partnerships
Amaero enters long-term supply agreement with Perryman
Additive Manufacturing
Yesterday
Product updates
Raise3D launches six new resins for DF2 DLP solution
Additive Manufacturing
Yesterday
M&A
Anzu Partners acquires voxeljet for EUR 20 million
Additive Manufacturing
Yesterday
Funding
Soda Health raises USD 50 million in oversubscribed Series B funding to scale operations
Health Benefits Platforms
Yesterday
AI Drug Discovery

AI Drug Discovery

Feb 22, 2021

AbSci receives strategic investment from Merck Global Health Innovation Fund

Partnerships

  • Washington-based synthetic biology company AbSci has received an investment of an undisclosed amount from Merck Global Health Innovation Fund. 

  • The investment is part of Merck’s initiative to invest in “Next Horizon” technologies that have the potential to disrupt the biopharmaceutical industry. The partnership will focus on the development of Denovium Engine, a deep learning artificial intelligence platform that AbSci took over in January 2021, and improving AbSci’s core drug discovery capabilities, such as non-standard amino acid technologies.

  • Founded in 2011, AbSci’s protein discovery and printing platform, SoluPro, is used to design soluble complex proteins and cell lines in a single efficient process. In January 2021, it acquired AI startup Denovium Inc. to leverage the latter’s capabilities in drug discovery and cell line development. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.